Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases
09 juin 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 9, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders
08 juin 2015 16h05 HE
|
Prothena Corporation plc
Investor Conference Call and Webcast to be Held Wednesday, June 17, 2015 at 5:30 p.m. EDT
DUBLIN, Ireland, June 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage...
Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting
02 juin 2015 12h15 HE
|
Prothena Corporation plc
Positive NEOD001 Phase 1/2 Results Further Support the Design of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial
Increase in Best Response Rate to 60% in 15 Renal-Evaluable...
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association
21 mai 2015 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 21, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting
13 mai 2015 17h05 HE
|
Prothena Corporation plc
Investor Conference Call and Webcast to be Held Tuesday, June 2, 2015 at 3:00 p.m. EDT
DUBLIN, Ireland, May 13, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage...
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update
05 mai 2015 16h05 HE
|
Prothena Corporation plc
Net cash used in operating activities was $14.7 million in the first quarter; net proceeds of $131.4 million raised through April 2015 public equity offering added to $279.9 million quarter-end...
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for Parkinson's Disease
04 mai 2015 16h05 HE
|
Prothena Corporation plc
NEW YORK and DUBLIN, Ireland, May 4, 2015 (GLOBE NEWSWIRE) -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical...
Prothena to Present at Upcoming Investor Healthcare Conferences
28 avr. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 28, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences
23 avr. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares
08 avr. 2015 06h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...